anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NACS scores do not specifically measure feeding behaviors, but rather the five general areas of adaptive capacity, passive tone, active tone, primary reflexes, and alertness/crying/motor activity. Conversely, the Preterm Infant Breastfeeding Behavior Scale (PIBBS)specifically examines neonatal rooting, latching, sucking, and swallowing behaviors as well as general activity level, thus producing a comprehensive picture of breast-feeding interactions.

Beilin et al. previously performed a randomized, controlled, double-blinded study of multiparous women who were randomized to receive intrapartum epidural analgesia that contained, in addition to bupivacaine, either greater than 150 micrograms total fentanyl, less than 150 micrograms, or zero. This study had several limitations. Breast-feeding difficulties were not assessed until 24 hours postpartum, long after the neonate would have been expected to have fully metabolized the drugs. Like most previous studies, Beilin et al. also did not control for skin-to-skin mother-infant contact. According to a prospective cohort study of 21,842 mothers in 19 hospitals, the likelihood of exclusive breast-feeding throughout the hospital stay is positively, significantly correlated with the number of minutes of skin-to-skin contact during the first three hours postpartum, even after controlling for intention to breast-feed at the time of hospital admission. Another randomized, controlled, double-blinded study found no significant differences regarding breast-feeding initiation or breast-feeding rates at 12 months postpartum among women who received bupivacaine-only epidural analgesia, combined spinal-epidural analgesia with mean fentanyl dose 107.3 micrograms, or epidural infusion with mean fentanyl dose 162.8 micrograms. All fentanyl was administered only as part of a continuous infusion and never in an initial bolus, so the potentially different effects resulting from large loading doses of fentanyl compared to gradual infusion could not be studied. The authors did not objectively measure neonatal feeding behavior, relying solely upon maternal interviewing at 24-48 hours post-delivery, and they studied only nulliparous women.

In a pilot study of 310 mothers who delivered at University Hospitals Case Medical Center (Cleveland, Ohio) between September 2009 and February 2010, we found that duration of epidural infusion was significantly correlated with decreased neonatal ability to successfully latch onto the breast and audibly swallow during the first three hours of life. All infusions contained identical doses of fentanyl and bupivacaine.
Inhibitors of the PI3 kinase pathway have demonstrated preclinical activity in neuroblastoma. This activity may derive in part from destabilizing Mycn protein, impeding tumor angiogenesis, and/or other effects. SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In preclinical studies, SF1126 results in marked concentration of LY294002 into tumors. In an adult phase 1 trial, a maximum tolerated dose of SF1126 was not identified up to doses of 1110 mg/m2 administered intravenously twice weekly on a continuous schedule. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated. All patients will participate in mandatory pharmacokinetic testing. Additional optional correlative studies will evaluate potential predictive markers and potential pharmacodynamic markers, including PTEN and PIK3CA aberrations, Myc / Mycn expression, and Myc / pS6 levels in peripheral blood mononuclear cells.
Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).
BACKGROUND: Although inappropriate gestational weight gain is considered closely related to adverse maternal and birth outcomes globally, little evidence was found in low- and middle-income countries. Study Objectives. This study is aimed at identifying the determinants of gestational weight gain and examine the association between gestational weight gain and maternal and birth outcomes in the Northern Region of Ghana. Study Methods. The study used a facility-based cross-sectional study design involving 611 antenatal and delivery records in Tatale district, Tamale west, and Gushegu municipal hospitals. A two-stage sampling method involving cluster and simple random sampling was employed. Descriptive statistical analysis and measures of central tendency were used to describe the sample. The multinomial logistic regression model was used to determine the determinants of gestational weight gain and its association with maternal and birth outcomes.
RESULTS: Among the 611 women included in the study, 516 (84.45%) had inadequate gestational weight gain, and 19 (3.11%) had excessive gestational weight gain. The gestational weight gain ranged from 2 kg to 25 kg with a mean of 7.26 ± 3.70 kg. The risk factor for inadequate gestational weight gain was low prepregnancy BMI (adjusted odds ratio (AOR) = 1.33, 95% CI = 1.18 - 2.57, P = 0.002). Pregnant women who had inadequate gestational weight gain were significantly less likely to deliver through caesarean section (AOR = 0.27, 95% CI = 0.12 - 0.61, P = 0.002), and those who had excessive weight gain were more likely to undergo caesarean section (AOR = 19.81, 95% CI = 5.38 - 72.91, P = 0.001). The odds of premature delivery (birth < 37 weeks) among pregnant women with inadequate weight gain were 2.88 (95% CI = 1.27 - 6.50, P = 0.011). Furthermore, subjects who had excessive weight gain were 43.80 times more likely to give birth to babies with macrosomia (95% CI = 7.07 - 271.23, P = 0.001).
CONCLUSION: Inappropriate gestational weight gain is prevalent in Ghana, which is associated with caesarean section, preterm delivery, delivery complications, and macrosomia. Urgent policy interventions are needed to improve on the frequent monitoring and management of gestational weight gain of pregnant women till term.
FIELD: medicine. ^ SUBSTANCE: invention belongs to medicine, notably, to gerontology, cardiology and can be used for pathologically raised biologic age in patients with arterial hypertension. To achieve this, rationally dosed static and dynamic physical exercises are administered, daily swimming in swimming pool at least 30 minutes daily and 10 mg of lisinopril daily in the morning. Course of treatment is 7 weeks. ^ EFFECT: combination of treatment methods ensures equalisation of biologic and chronologic ages, thus improving quality of life in this group of patients. ^ 2 ex, 1 dwg
If antiviral treatment is efficient in halting the disease progression, it will be to great benefit for the participating patients. Maintenance or even an increase in beta cell mass due to regeneration will lead to improved endogenous insulin production and give a milder course of the disease with improved glycemic control. This will in a substantial way improve the long-term prognosis with less severe long term vascular complications.Some patients may have close to complete remission and be able to stop insulin treatment. If antiviral treatment is effective, it would add proof to the concept that type 1 diabetes in its origin is a viral disease. This would be an important milestone in medical research and a breakthrough in the understanding of the etiopathogenesis of autoimmune diseases. It may promote the development of vaccines to prevent the disease. T1D seems more aggressive in children than in adults, and the beta cell function decline rapidly compared to adults. As a consequence, the effect of antiviral treatment will potentially be more significant in children than in adults. Children have higher HbA1c which increases the risk of complications. Thus, T1D is a more aggressive disease in children than in adults and hence it's important to do this study in children. Pharmaceuticals are usually studied in different age intervals, commonly 1-6 years, 6-12 years and 12-15 years. For safety reasons and simplicity, the investigators want to start with the two older groups. The investigators will treat the participants with two antiviral medications (Pleconaril and ribavirin) or placebo in a double blind, randomized, placebo controlled, parallel group study. Pleconaril has previously been given in doses of 5-10mg/kg x 2-3 in clinical trials in children, thus achieving serum levels high enough for killing the majority of the viruses. The investigators have, due to the long treatment period, reduced the doses to 5 mg/kg x 2. Ribavirin will be given in dosages according to Summariy of product characteristics (SmPC). The investigators have chosen to administer Investigational Medicinal Product (IMPs) as an oral solution as this will make it easier to give the medication according to weight.
The ICBN is a cutaneous sensory nerve that supplies the medial aspect of the upper arm. Traditionally this nerve is blocked to alleviate tourniquet pain. The etiology of tourniquet pain is complex and the study team hypothesize that blocking the ICBN has no impact on tourniquet pain. Patients will receive a supraclavicular block and be divided into two groups; ICBN with local anesthetic or ICBN with saline. All patients in this study will receive a supraclavicular block as their primary anesthetic and then be divided into two groups; those who receive ICBN and those who do not. Amount of intraoperative analgesics, conversion to deep sedation or general anesthesia, and onset of time to tourniquet pain will be the primary measures of this study.
Polluted resources of potable water are daily used for different purposes in Lebanon. The optical microscopy is the traditional method used for the detection of Entamoeba spp. in water despite its weak sensitivity. We aimed to characterize domestic water at Nabatieh district, South Lebanon, and to develop a simple method for Entamoeba spp. detection. A total of 70 water samples were collected from houses and schools and analyzed for physical (pH, total dissolved solids and temperature), chemical (nitrate, phosphate and sulfate) and bacterial (total and fecal coliforms) parameters. The contamination by Entamoeba spp. was examined using microscopy, then a spectrophotometric wavelength scan was recorded for 50 samples in order to determine the common peak between positive samples. High phosphate levels were detected in all the samples, with important bacterial and parasitological contaminations. The spectrophotometric analyses showed a peak repetition at the wavelength of 696 nm in the spectrum of the majority of positive samples. The number of cysts was significantly correlated to optical densities at 696 nm (R = 0.9087; p-value<0.0001). The regression analysis showed that the OD696 could statistically predict the concentration (F (1,48) = 267.02, p-value <0.001). In conclusion, potable water parameters at Nabatieh district did not meet the national and international guidelines of safe drinking water, and the detection of Entamoeba spp. cysts in potable water can be performed using a rapid spectrophotometric analysis, by the determination of the optical density at 696 nm and the application of a specific equation.
Systems and methods for non-prescription delivery of statins to a subject are provided. Run 5 findings from the subject against a first plurality of filters. When a filter of the first plurality of filters is activated, the subject is considered ineligible. The survey results are also run against a second plurality of filters. Providing a corresponding alert to the subject when a respective filter of the second plurality of filters is activated. When none of the first plurality of filters is fired and the subject has confirmed each alert associated with each fired filter of the second plurality of filters, the method continues to a fulfillment process. The fulfillment of the storage composition order, the communication of a drug fact tag of the statin to the subject, and the authorization to provide the statin to the subject upon the subject confirming that the tag has been read, the authorization including a destination associated with the subject.
Participant will be randomized into the RGM study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being diabetes self-management training (DSMT).
Limited information is available regarding the prevalence of pressure ulcers (PUs) in residential homes in Central Asia. Therefore, the aim of this study was to identify the prevalence rates and risk factors associated with PUs among residents of long-term care medical institutions in the Republic of Kazakhstan. This cross-sectional study was conducted in four long-term care institutions in Kazakhstan. The study sample consisted of 640 patients who were assessed for the presence of PUs and associated risk factors. The evaluation was performed using the International Prevalence Measurement of Care Quality (Landelijke Prevalentiemeting Zorgkwaliteit, LPZ), the Braden scale, and the Care Dependency Score (CDS). The overall prevalence of PUs, classified as categories I-IV, was found to be 37%. When excluding category I PUs, the prevalence decreased to 35.6%. The odds ratios (ORs) for presenting with PUs were as follows: history of stroke (OR 5.22), diseases of the digestive system (OR 10.01), presence of spinal cord lesions/paraplegia (OR 20.50), recent reported confusion within the last 7 days (OR 184.00), and limited extent dependency according to the CDS (OR 4.44; 95%CI 1.31-16.1). It is imperative to establish specialized training programs aimed at equipping medical personnel, relatives, and patients themselves with the necessary skills to provide optimal care for individuals affected by PUs.
A substance having the physiological activity of folic acid is prepared by causing an organism selected from the group consisting of Streptococcus lactis, Streptococcus faecalis and Streptococcus zymogens to act in an aqueous solution of rhizopterin (a pterin-like acidic body obtained from fumaric acid fermentation liquors) at 30-40 DEG  C. in a substantially oxygen free atmosphere.  Growing and resting organisms may be used.  In the former case a nutrient medium is employed comprising in addition to rhizopterin assimilable sources of carbon (e.g. sugars such as glucose and levulose and the glucoside salicin), nitrogen e.g. amino acids (such as cysteine and adenine), minerals (e.g. manganese, iron and magnesium sulphates; potassium monodiphosphates) and vitamins (e.g. water soluble B group). With a suitable initial concentration of rhizopterin the bulk of the folic acid will be found outside the organism cell and may be obtained therefrom by centrifuging the culture.  With resting, fully-grown organisms it is thereby necessary to treat the cells, preferably buffered at pH8, in an aqueous solution of rhizopterin containing glucose and through which an inert gas is passed, and to centrifuge off the cells, which can be used as such or the folic acid obtained therefrom by autolysis and subsequent purification.ALSO:A substance having the physiological activity of folic acid is prepared by causing an organism selected from the group consisting of Streptococous lactis, Streptococous faecalis and Streptococous zymogens to act in an aqueous solution of rhizopterin (a pterin-like acidic body obtained from fumaric acid fermentation liquors) at 30-40 degrees in a substantially oxygen free atmosphere.  Growing and resting organisms may be used.  In the former case a nutrient medium is employed comprising in addition to rhizopterin assimilable sources of carbon (e.g. sugars such as glucose and levulose and the glucoside salicin), nitrogen (e.g. amino acids such as cystine and adenine), minerals (e.g. manganese iron and magnesium sulphates; potassium monodi-phosphates) and vitamins (e.g. water soluble B group).  With a suitable initial concentration of rhizopterin the bulk of the folic acid will be found outside the organism cell and may be obtained therefrom by centrifuging the culture.  With resting, fully-grown organisms it is merely necessary to treat the cells, preferably buffered at pH8, with an aqueous solution of rhizopterin containing glucose, through which an inert gas is passed and to centrifuge off the cells, which can be used as such or the folic acid obtained therefrom by autolysis and subsequent purification.
Subjects randomized to morphine in a 1:1 ratio. Intermittent dosing every 3-4 hours of 0.02-0.05 mg/kg/dose or continuous infusion of 0.005 to 0.01 mg/kg/hr. The N-PASS will be used to determine dosing and frequency.
Clinically meaningful pharmacokinetic interaction between INVEGA SUSTENNA and valproate (including valproic acid and divalproex sodium) is not expected. Based on pharmacokinetic studies with oral paliperidone, no dosage adjustment of INVEGA SUSTENNA is required when administered with valproate [see Clinical Pharmacology (12.3)]. Additionally, no dosage adjustment is necessary for valproate when co-administered with INVEGA SUSTENNA [See Clinical Pharmacology (12.3)]. 

Pharmacokinetic interaction between lithium and INVEGA SUSTENNA is also unlikely.

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitrostudies indicate that CYP2D6 and CYP3A4 may be involved in paliperidone metabolism; however, there is no evidence in vivothat inhibitors of these enzymes significantly affect the metabolism of paliperidone. Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19; an interaction with inhibitors or inducers of these isozymes is unlikely. [see Clinical Pharmacology (12.3)]
Pain is a debilitating phenomenon that dramatically impairs the quality of life of patients. Many chronic conditions, including cancer, are associated with chronic pain. Despite pharmacological efforts that have been conducted, many patients suffering from cancer pain remain without treatment. To date, opioids are considered the preferred therapeutic choice for cancer-related pain management. Unfortunately, opioid treatment causes side effects and inefficiently relieves patients from pain, therefore alternative therapies have been considered, including Cannabis Sativa and cannabinoids. Accumulating evidence has highlighted that an increasing number of patients are choosing to use cannabis and cannabinoids for the management of their soothing and non-palliative cancer pain and other cancer-related symptoms. However, their clinical application must be supported by convincing and reproducible clinical trials. In this review, we provide an update on cannabinoid use for cancer pain management. Moreover, we tried to turn a light on the potential use of cannabis as a possible therapeutic option for cancer-related pain relief.
A sterilisable gel formulation comprises calcium gluconate and may be stable under gamma-radiation sterilisation conditions. The gel may comprise carbomer powder or xanthan gum; it may be used to treat burns caused by exposure to hydrofluoric acid (HF), either in liquid or vapour form. The gel formulation may be produced by dissolving calcium gluconate in water, adding a gelling agent, mixing to make homogeneous and adjusting the pH to between 5 and 8. The gel may be sterilized using gamma irradiation. An exemplified gel comprises xanthan gum, calcium gluconate, citric acid, potassium sorbate and phenoxyethanol. A further exemplified gel comprises carbomer polymer, calcium gluconate, sodium hydroxide and water.
* Be sure to take ropinirole hydrochloride tablets exactly as directed by your doctor or healthcare provider. 
  * The usual way to take ropinirole hydrochloride is once in the evening, 1 to 3 hours before bedtime. 
  * Your doctor will start you on a low dose of ropinirole hydrochloride tablets. Your doctor may change the dose until you are taking the amount of medicine that is right for you to control your symptoms. 
  * You may receive a starting kit with doses marked by day. The pills in this kit slowly increase your daily dose over time so that you and your doctor may determine what the best dose is for you. Different people respond differently to this medicine. You may not need the highest dose pill in this kit or you may need an even higher dose to relieve your symptoms. You should carefully follow your doctor’s advice on the use of this kit.
  * If you miss your dose, do not double your next dose. Take only your usual dose 1 to 3 hours before your next bedtime. 
  * Contact your doctor, if you stop taking ropinirole hydrochloride for any reason. Do not restart without consulting your doctor. 
  * You can take ropinirole hydrochloride with or without food. Taking ropinirole hydrochloride with food may decrease the chances of feeling nauseated.
Huntington disease (HD) is a hereditary neurodegenerative disorder with a hallmark feature of chorea. While no disease-modifying therapies currently exist for HD, symptomatic treatment of HD-associated chorea includes US Food and Drug Administration-approved vesicular monoamine transporter type 2 inhibitors-tetrabenazine and deutetrabenazine. Deutetrabenazine was more recently approved (2017), and while structurally similar to tetrabenazine, deutetrabenazine has a unique pharmacokinetic profile that allows for a longer half-life, reduced plasma fluctuations, and less frequent dosing. In pivotal trials, deutetrabenazine seemed to have an improved safety and tolerability profile over tetrabenazine but real-world data to confirm this are lacking. Here, we evaluate our real-world clinical experience with deutetrabenazine for HD-associated chorea. We performed a retrospective chart review of all patients with HD who initiated treatment with deutetrabenazine from January 2017 to May 2019 at the University of Alabama at Birmingham. Total maximal chorea scores, patient-reported subjective efficacy, dosing information, and subjective reports of adverse events (AEs) were abstracted for each patient. Our review included 58 patients with a mean length of treatment of 476.4 days. In the reviewed time period, the mean treatment difference in total maximal chorea scores was 4.4. The combined total rate of occurrence of any AEs was relatively low, at 32.8%, and the most commonly reported AEs were sedation (15.5%), insomnia (6.9%), and diarrhea (3.4%). Our real-world data support current literature indicating that deutetrabenazine is an effective and well-tolerated treatment for HD-associated chorea. Further studies repeating this on a larger scale, across a greater geography and practice pattern, are needed.